FDA accepts resubmitted NDA for Apricus' Vitaros

FDA accepted for review a resubmitted NDA for Vitaros alprostadil from Apricus Biosciences Inc.

Read the full 149 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE